Lexicon Pharmaceuticals Market Cap: 575.74M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
LXRX Market Cap Rankings
| Overall | 50th percentile | 2320 of 4673 |
| Sector | 64th percentile | 187 of 530 in Healthcare |
| Industry | 74th percentile | 42 of 164 in Biotechnology |
LXRX Market Cap Range, Past 5 Years
| Minimum | 208.96M | Mar 2003 |
| Maximum | 802.28M | Dec 2000 |
| Average |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these LXRX related companies
LXRX News
Lexicon Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference
Feb 07, 6:00PM PR Newswire
Feb 07, 6:00PM PR Newswire
Lexicon Pharmaceuticals' CEO Presents at JP Morgan Healthcare Conference (Transcript)
Jan 11, 8:42PM Seeking Alpha
Jan 11, 8:42PM Seeking Alpha
Lexicon (LXRX) Says Top-Line Results from LX4211 Study Show Enhanced Effects with DPP-4
Jan 09, 4:41PM Street Insider
Jan 09, 4:41PM Street Insider
LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes
Jan 09, 4:30PM Benzinga
Jan 09, 4:30PM Benzinga
Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 04, 6:00PM PR Newswire
Jan 04, 6:00PM PR Newswire
Lexicon Pharmaceuticals (LXRX) Completes Offering with Gross Proceeds of $161 Million
Dec 23, 8:31AM Street Insider
Dec 23, 8:31AM Street Insider
FMR LLC Raises Stake in Lexicon Pharmaceuticals, Inc. (LXRX) to 17.55%
Dec 12, 11:43AM Street Insider
Dec 12, 11:43AM Street Insider
Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
Nov 03, 6:00PM PR Newswire
Nov 03, 6:00PM PR Newswire
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Q3 Review
Nov 02, 8:20AM Street Insider
Nov 02, 8:20AM Street Insider
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
Nov 01, 6:00AM PR Newswire
Nov 01, 6:00AM PR Newswire
Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
Oct 27, 6:00PM PR Newswire
Oct 27, 6:00PM PR Newswire
$LXRX http://stks.co/ZAO Hammer candle. Flagging at the 20MA. Like it with volume expansion.
about 125 days ago by VexTrades
about 125 days ago by VexTrades
$LXRX http://chart.ly/d5ep8gf hvy EOD volume. looks like a solid break out so far.
about 233 days ago by traderengineer
about 233 days ago by traderengineer
$LXRX http://chart.ly/uo3em8f jumped in. breaking trend on volume.
about 233 days ago by traderengineer
about 233 days ago by traderengineer
$LXRX http://chart.ly/ibwtlnq close to breakout.... nice action all day in this crap tape....
about 234 days ago by stt2318
about 234 days ago by stt2318
Top Rankings for Biotech and Generic Drug Companies - Zacks Industry Rank Analysis
Nov 12, 12:00AM Zacks
Nov 12, 12:00AM Zacks
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| LXRX | 1.71 | -0.01 | -0.29% | 575.74M |
| DLIA | 1.10 | 0.01 | 0.92% | 34.57M |
| IACI | 45.05 | -0.32 | -0.71% | 3.70B |
| MKTX | 32.23 | 0.19 | 0.59% | 1.14B |
| ACAS | 8.69 | 0.15 | 1.76% | 3.00B |
| HBAN | 5.91 | -0.12 | -2.07% | 5.10B |
| HMIN | 31.06 | -0.31 | -0.99% | 1.23B |
| BIDZ | 0.55 | 0.02 | 3.75% | 10.66M |
| ISIL | 11.15 | -0.26 | -2.28% | 1.41B |
| VISN | 1.50 | -0.08 | -5.06% | 153.38M |
